PT946151E - Forma de dosagem de dose crescente - Google Patents

Forma de dosagem de dose crescente

Info

Publication number
PT946151E
PT946151E PT97947642T PT97947642T PT946151E PT 946151 E PT946151 E PT 946151E PT 97947642 T PT97947642 T PT 97947642T PT 97947642 T PT97947642 T PT 97947642T PT 946151 E PT946151 E PT 946151E
Authority
PT
Portugal
Prior art keywords
dosage form
growing
dose
growing dose
delivering
Prior art date
Application number
PT97947642T
Other languages
English (en)
Portuguese (pt)
Inventor
Lawrence G Hamel
Ayer Atul Devdatt
Jeri D Wright
Andrew Lam
Padmaja Shivanand
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26707551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT946151(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT946151E publication Critical patent/PT946151E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97947642T 1996-11-25 1997-11-12 Forma de dosagem de dose crescente PT946151E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3174196P 1996-11-25 1996-11-25
US96760697A 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
PT946151E true PT946151E (pt) 2006-07-31

Family

ID=26707551

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97947642T PT946151E (pt) 1996-11-25 1997-11-12 Forma de dosagem de dose crescente

Country Status (11)

Country Link
EP (1) EP0946151B1 (enExample)
JP (2) JP5173089B2 (enExample)
CN (2) CN100477986C (enExample)
AT (1) ATE325606T1 (enExample)
AU (1) AU5267698A (enExample)
CA (1) CA2265668C (enExample)
DE (1) DE69735848T2 (enExample)
DK (1) DK0946151T3 (enExample)
ES (1) ES2264173T3 (enExample)
PT (1) PT946151E (enExample)
WO (1) WO1998023263A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
HUP0600680A3 (en) 2001-12-24 2008-04-28 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
WO2010077925A2 (en) 2008-12-16 2010-07-08 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
DK4011364T3 (da) 2011-03-23 2024-03-18 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder)
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
EP0540623B1 (en) * 1990-07-23 1994-09-14 Alza Corporation Oral osmotic device for delivering nicotine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
WO1998006380A2 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug

Also Published As

Publication number Publication date
JP2010215632A (ja) 2010-09-30
DE69735848T2 (de) 2006-12-28
JP2002513392A (ja) 2002-05-08
CN1233953A (zh) 1999-11-03
ATE325606T1 (de) 2006-06-15
AU5267698A (en) 1998-06-22
HK1021620A1 (en) 2000-06-23
JP5173089B2 (ja) 2013-03-27
CN100477986C (zh) 2009-04-15
EP0946151A1 (en) 1999-10-06
WO1998023263A1 (en) 1998-06-04
DK0946151T3 (da) 2006-08-28
DE69735848D1 (de) 2006-06-14
ES2264173T3 (es) 2006-12-16
EP0946151B1 (en) 2006-05-10
CA2265668A1 (en) 1998-06-04
CN1182839C (zh) 2005-01-05
CN1636552A (zh) 2005-07-13
CA2265668C (en) 2005-08-23
JP5215347B2 (ja) 2013-06-19

Similar Documents

Publication Publication Date Title
PT946151E (pt) Forma de dosagem de dose crescente
DE69735581D1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
DE69720055D1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
IL206830A (en) Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
NZ508526A (en) Opioid formulations for treating pain
DE69814394D1 (de) Verwendung von levobupivacain
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
IL117809A0 (en) Medical patch for rate-controlled transdermal administration of risperidone
AR003979A1 (es) Administracion transdermica de vorozol.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
SE9904424D0 (sv) Use of interleukin-6 in combination with leptin in treatment of obesity
ATE292458T1 (de) Transdermales therapeutisches system zur verabreichung von (s)-3-methyl-5-(1-methyl-2- pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen salze
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
MX9603833A (es) Tratamiento mejorado del cancer con temozolomida.
UA30251A (uk) Спосіб лікування гіпертонії сфінктера одді у хворих на хронічний безкам'яний холецистит при поєднанні з підвищенням тонусу симпатичної нервової системи
UA35918A (uk) Спосіб лікування червоного плескатого лишаю слизової оболонки порожнини рота
UA29005A (uk) Спосіб лікування трофічних виразок нижніх кінцівок
EP1690531A3 (en) Dosage form and method for administering drug